Paul Wu

Paul Wu is a life-sciences investor and operator who served as a Partner at Grey Sky Venture Partners (GSVP), an early-stage investment fund headquartered in Bellevue, Washington, with an additional office in Silicon Valley. At GSVP he led early-stage investments focused on health, biotechnology, and digital companies, working alongside fellow partners Michael Banks and Todd McIntyre. The firm positioned itself as providing both capital and intellectual property to entrepreneurs building next-generation life sciences companies, taking an active, engaged, company-building approach — reflecting roots in the invention/IP ecosystem of the Bellevue area (home to Intellectual Ventures and its Invention Science Fund).

His background spans venture capital, strategic business development, and entrepreneurship. He holds an MBA from the MIT Sloan School of Management and a Ph.D. in Biomedical Engineering from Northwestern University, giving him a combination of deep technical/scientific training and business education that maps directly onto GSVP's deep-tech life sciences mandate.

In 2022, Paul Wu joined Eisai Innovation Inc.—the venture and innovation arm of the Japanese pharmaceutical company Eisai—as an Investment Principal based in its San Francisco office, where he works on venture capital and strategic investing in the healthcare and biotech space. GSVP's own investing activity appears to have wound down (its last recorded transactions date to around 2020), and Paul Wu's primary current role is at Eisai Innovation.

• Invests at the seed and early stage in life sciences and healthcare startups — the profile the original data captures as "angel / seed round."
• Sector focus on biotechnology, medical devices and diagnostics, drug delivery, and digital health, consistent with his biomedical-engineering doctorate.
• GSVP's stated approach: *"providing capital and intellectual property to passionate entrepreneurs building innovative, next-generation life sciences companies"* — pairing money with IP and hands-on company-building.
• Values companies with strong underlying science and defensible IP; the firm emphasizes an "active and engaged approach to company building and value creation" rather than passive check-writing.
• Comfortable with technically complex, deep-science businesses (diagnostics platforms, drug-delivery chemistry) that require a scientifically literate investor.